Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $357.27 --0%
EPS Growth %: +22.2%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
OMID, SICP, SCKT, More
EPS Growth %: +22.2%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.82, $0.08 better than the analyst estimate of $0.74. Revenue for the quarter came in at $299.4 million versus the consensus estimate of $302.08 million.
Charles River Laboratories sees FY2014 EPS of $3.15 - $3.25, versus prior guidance of $.00 - $3.10. Sees sales growth of 9 to 11 percent, from 3 to 5 percent prior.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CTS Corp. (CTS) Tops Q3 EPS by 10c ; Offers Guidance
- Repligen (RGEN) Tops Q3 EPS by 7c ; Offers Guidance
- Sherwin-Williams (SHW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
